resectable NSCLC Archives - GO2 for Lung Cancer

FDA Approves Neoadjuvant & Adjuvant Imfinzi (durvalumab) for Resectable NSCLC

On August 15, 2024, the U.S. Food and Drug Administration (FDA) granted approval for the immunotherapy drug Imfinzi (durvalumab) to be used in combination with chemotherapy (neoadjuvant, treatment given before surgery) as well as on its own after surgery (adjuvant). [...]

FDA Approves New Treatment Regimen for Individuals Receiving Keytruda (pembrolizumab) for Resectable Non-Small Cell Lung Cancer

Bethany Johnson (GO2 for Lung Cancer)2023-10-18T11:45:37-05:00October 18th, 2023|Hot Topics, News, Science and Research|

On October 16, 2023, the U.S. Food and Drug Administration (FDA) approved a new treatment plan for people receiving Keytruda (pembrolizumab) for resectable non-small cell lung cancer (NSCLC). This approval is based on results from the KEYNOTE-671 (NCT03425643) clinical [...]